Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 72 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 43% bearish. Among these notable options, 14 are puts, totaling $1,035,193, and 58 are calls, amounting to $13,672,379.
Expected Price Movements
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $500.0 to $1380.0 for Eli Lilly during the past quarter.
Analyzing Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale activity within a strike price range from $500.0 to $1380.0 in the last 30 days.
Eli Lilly Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | CALL | TRADE | BULLISH | 06/17/27 | $134.3 | $131.3 | $134.3 | $1000.00 | $671.5K | 62 | 50 |
| LLY | CALL | TRADE | BEARISH | 01/15/27 | $155.0 | $151.0 | $151.0 | $900.00 | $226.5K | 140 | 15 |
| LLY | PUT | SWEEP | BULLISH | 01/15/27 | $44.9 | $38.7 | $42.0 | $600.00 | $210.0K | 843 | 50 |
| LLY | PUT | SWEEP | BEARISH | 07/18/25 | $45.9 | $44.85 | $46.1 | $830.00 | $138.2K | 112 | 32 |
| LLY | CALL | TRADE | BULLISH | 04/25/25 | $10.55 | $10.15 | $10.55 | $850.00 | $104.4K | 1.4K | 2.1K |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Current Position of Eli Lilly
- With a volume of 1,282,995, the price of LLY is up 3.08% at $854.96.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 7 days.
Professional Analyst Ratings for Eli Lilly
4 market experts have recently issued ratings for this stock, with a consensus target price of $978.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Morgan Stanley has decided to maintain their Overweight rating on Eli Lilly, which currently sits at a price target of $1124. * Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Eli Lilly with a target price of $928. * An analyst from Goldman Sachs has elevated its stance to Buy, setting a new price target at $888. * An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $975.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from Benzinga Pro.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
